FURTHER OPTIMIZING 2ND GENERATION DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR T CELLS TO ACHIEVE CURES OF ADVANCED CCRCC.

Dana-Farber Cancer Institute, Inc.

Investigators